HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hetzel, M Articles by Marx, N Search for Related Content PubMed PubMed Citation Articles by Hetzel, M Articles by Marx, N Topic Collections Relevant Article

Inhibition of MMP-9 expression by PPAR activators in human bronchial epithelial cells

Department of Internal Medicine II, University of Ulm, Germany

Correspondence to:
Correspondence to:
Dr M Hetzel, Department of Internal Medicine II, University of Ulm, Robert-Koch-Strasse 8, D-89081 Ulm, Germany;
martin.hetzel{at}medizin.uni-ulm.de

ABSTRACT
Background: The release of matrix degrading enzymes such as matrix metalloproteinase 9 (MMP-9) from bronchial epithelial cells is critically involved in airway wall remodelling in chronic inflammatory processes of the respiratory system. MMP-9 expression is induced by inflammatory mediators such as tumour necrosis factor (TNF)-, but to date nothing is known about the mechanisms of inhibition of MMP-9 expression in these cells.

Methods: A study was undertaken to examine whether activators of the nuclear transcription factor peroxisome proliferator activated receptor gamma (PPAR) might modulate MMP-9 expression in two different bronchial epithelial cell lines.

Results: PPAR was expressed and was functionally active in NL20 and BEAS cells. Activation of PPAR by rosiglitazone or pioglitazone significantly reduced TNF- and PMA induced MMP-9 gelatinolytic activity in a concentration dependent manner in both cell lines, but did not alter the expression of tissue inhibitor of MMPs type 1 (TIMP-1), the local inhibitor of MMP-9. Northern blot analysis revealed a decrease in MMP-9 mRNA expression following treatment with PPAR which resulted from the inhibition of NF-B activation in these cells, as determined by transient transfection assays and electromobility shift assays.

Conclusion: Activation of PPAR in human bronchial epithelial cells limits the expression of matrix degrading MMP-9. This might have therapeutic applications in chronic inflammatory processes of the respiratory system.

Keywords: matrix metalloproteinase (MMP)-9; peroxisome proliferator activated receptor (PPAR)

Relevant Article

Airwaves

Wisia Wedzicha
Thorax 2003 58: 739. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				S Soumian, R Gibbs, A Davies, and C Albrecht mRNA expression of genes involved in lipid efflux and matrix degradation in occlusive and ectatic atherosclerotic disease J. Clin. Pathol., December 1, 2005; 58(12): 1255 - 1260. [Abstract] [Full Text] [PDF]

				N. P. Kadoglou, S. S. Daskalopoulou, D. Perrea, and C. D. Liapis Matrix Metalloproteinases and Diabetic Vascular Complications Angiology, March 1, 2005; 56(2): 173 - 189. [Abstract] [PDF]

				M. Francois, P. Richette, L. Tsagris, M. Raymondjean, M.-C. Fulchignoni-Lataud, C. Forest, J.-F. Savouret, and M.-T. Corvol Peroxisome Proliferator-activated Receptor-{gamma} Down-regulates Chondrocyte Matrix Metalloproteinase-1 via a Novel Composite Element J. Biol. Chem., July 2, 2004; 279(27): 28411 - 28418. [Abstract] [Full Text] [PDF]